PTC Therapeutics Inc launches the fifth annual STRIVE Awards grant program to provide funds for patient advocacy organizations around the world to develop programs that impact the lives of people with Duchenne muscular dystrophy.

Since its inception, STRIVE has supported more than 20 programs that have directly impacted the lives of people living with Duchenne, addressing some of the greatest areas of unmet need. The programs have improved access to diagnostic testing, supported independent living and personal empowerment, educated families and healthcare professionals, provided psychological support via a range of online platforms, and provided much-needed opportunities for respite, according to a news release from PTC Therapeutics Inc, based in South Plainfield, NJ.

“With funding from the STRIVE Awards last year, we were able to provide educational meetings and access to specialized healthcare professionals in support of families affected by Duchenne in Hungary,” says Gabriella Oberrecht, Duchenne Hungary, in the release. “The PTC STRIVE program provides a great opportunity for the Duchenne community to help realize their goals, and we encourage local organizations to submit their proposals this year to support families living with Duchenne.”

“Now in its fifth year, we are proud that the STRIVE Awards Program continues to support the Duchenne community. Past winners have helped carers, healthcare professionals, and families,” states Mary Frances Harmon, senior vice president, corporate relations, PTC Therapeutics.

“Through the proposals we receive each year, we see innovative solutions for the complex challenges faced by this community, and we are excited to see the proposals that are submitted this year.”

The program is aimed at improving the diagnosis and treatment of Duchenne patients, increasing the visibility of this disorder and educating the general public and healthcare professionals, as well as identifying and fostering the next generation of Duchenne patient advocates.

The application process for the program is now open to Patient Advocacy Organizations, and the deadline for submission of proposals is April 30, 2019. Recipients of the awards will be announced later this year in conjunction with World Duchenne Awareness Day.

For more information about the criteria for applications, selection process, and how to apply, visit PTC Therapeutics Inc.

[Source(s): PTC Therapeutics Inc, PR Newswire]